LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Lakefront Biotherapeutics NV
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$29.79−0.11 (-0.37%)
Close on Oct 19, 2026
Lakefront Biotherapeutics NV revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fee for services segment | – | – | – | – | – | – | €10.08M | €10.17M | €8.83M | €7.90M | – | – |
| Research and Development Segment | – | – | – | – | – | – | €834.90M | €278.67M | €118.26M | €121.62M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fee for services segment | – | – | – | – | – | – | €1.13M | €1.75M | €86.00K | -€1.79M | – |
| Research and Development Segment | – | – | – | – | – | – | €407.46M | -€19.73M | -€73.61M | €1.14M | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | €472.45M | €793.87M | €116.68M | €82.05M | €88.63M | – | – |
| Europe | – | – | – | – | – | €5.61M | €41.03M | €161.99M | €45.04M | €40.88M | – | – |
| Asia Pacific | – | – | – | – | – | – | €362.00K | €114.00K | – | €6.00K | – | – |
| North America | – | – | – | – | – | – | €795.61M | €117.61M | €82.05M | – | – | – |
From the segment and revenue-disaggregation notes of Lakefront Biotherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.